89bio Inc.

25.32+0.5500+2.22%Vol 105.30K1Y Perf 11.17%
Apr 19th, 2021 16:00 DELAYED
BID25.30 ASK25.41
Open24.69 Previous Close24.77
Pre-Market- After-Market-
 - -  - -%
Target Price
62.00 
Analyst Rating
Strong Buy 1.33
Potential %
144.87 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap505.03M 
Earnings Rating
Price Range Ratio 52W %
30.02 
Earnings Date
12th May 2021

Today's Price Range

24.6925.72

52W Range

18.0142.36

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
7.70%
1 Month
0.92%
3 Months
19.94%
6 Months
5.94%
1 Year
11.17%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ETNB25.320.55002.22
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.90-0.6330.00
Q03 2020-0.89-0.863.37
Q02 2020-0.85-0.850.00
Q01 2020-0.92-0.7617.39
Q04 2019-0.81-2.58-218.52
Q03 2019-0.85-30.63-3 503.53
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date12th May 2021
Estimated EPS Next Report-0.67
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume105.30K
Shares Outstanding19.95M
Trades Count1.38K
Dollar Volume4.61M
Avg. Volume152.34K
Avg. Weekly Volume94.18K
Avg. Monthly Volume108.37K
Avg. Quarterly Volume125.37K

89bio Inc. (NASDAQ: ETNB) stock closed at 25.32 per share at the end of the most recent trading day (a 2.22% change compared to the prior day closing price) with a volume of 105.30K shares and market capitalization of 505.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. 89bio Inc. CEO is Rohan Palekar.

The one-year performance of 89bio Inc. stock is 11.17%, while year-to-date (YTD) performance is 3.9%. ETNB stock has a five-year performance of %. Its 52-week range is between 18.01 and 42.36, which gives ETNB stock a 52-week price range ratio of 30.02%

89bio Inc. currently has a PE ratio of -8.10, a price-to-book (PB) ratio of 2.43, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.29%, a ROC of -70.24% and a ROE of -33.80%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from 89bio Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. 89bio Inc.’s next earnings report date is 12th May 2021.

The consensus rating of Wall Street analysts for 89bio Inc. is Strong Buy (1.33), with a target price of $62, which is +144.87% compared to the current price. The earnings rating for 89bio Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

89bio Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

89bio Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.68, ATR14 : 1.56, CCI20 : 52.79, Chaikin Money Flow : -0.06, MACD : 0.28, Money Flow Index : 60.99, ROC : 6.93, RSI : 47.19, STOCH (14,3) : 67.59, STOCH RSI : 0.95, UO : 45.59, Williams %R : -32.41), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of 89bio Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
2 (66.67 %)
Moderate Buy
1 (33.33 %)
1 (33.33 %)
1 (33.33 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.33

89bio Inc.

89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, BIO89-100, is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.

CEO: Rohan Palekar

Telephone: +1 415 500-4614

Address: 142 Sansome Street, San Francisco 94104, CA, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

61%39%

Bearish Bullish

39%61%

Bearish Bullish

58%42%

News

Stocktwits